Universidad Autónoma de Madrid-ko ikertzaileekin lankidetzan egindako argitalpenak (15)

2024

  1. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 12, Núm. 10, pp. 2648-2668.e2

2023

  1. C-Type Lectin Receptor Mediated Modulation of T2 Immune Responses to Allergens

    Current Allergy and Asthma Reports, Vol. 23, Núm. 3, pp. 141-151

  2. Cannabinoid WIN55,212-2 reprograms monocytes and macrophages to inhibit LPS-induced inflammation

    Frontiers in Immunology, Vol. 14

  3. Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN-α production and FOXP3+ Treg generation

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 4, pp. 1060-1072

  4. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 5, pp. 1169-1203

2021

  1. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy

    Clinical and Translational Allergy, Vol. 11, Núm. 4

  2. EAACI Biologicals Guidelines—Recommendations for severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 14-44

  3. Management of anaphylaxis due to COVID-19 vaccines in the elderly

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 10, pp. 2952-2964

2020

  1. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1043-1057

  2. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1023-1042

  3. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1058-1068

2015

  1. An enzymatically active β-1,3-glucanase from ash pollen with allergenic properties: A particular member in the oleaceae family

    PLoS ONE, Vol. 10, Núm. 7

2014

  1. Immune regulation by intralymphatic immunotherapy with modular allergen translocation MAT vaccine

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 69, Núm. 9, pp. 1162-1170

  2. Regulatory T cells and immune regulation of allergic diseases: Roles of IL-10 and TGF-β

    Genes and Immunity, Vol. 15, Núm. 8, pp. 511-520

2006

  1. Hypersensitivity to black locust (Robinia pseudoacacia) pollen: "Allergy mirages"

    Annals of Allergy, Asthma and Immunology, Vol. 96, Núm. 4, pp. 586-592